BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Hope Springs Eternal for Inflammatory Disease Treatments at AAD 2022

  The 2022 American Academy of Dermatology Annual Meeting saw several milestones for treatment explorations for inflammatory diseases. Here is some of the major news:

  March 28, 2022

   · 

  4 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  FDA Greenlights UCB Drug for Severe Form of Epilepsy

  UCB’s oral drug for seizures related to Lennox-Gastaut syndrome is now approved in the U.S. for patients ages two years and older.

  March 28, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Axsome Strikes Deal for Narcolepsy Drug with High Growth Potential

  The acquisition of Sunosi transforms Axsome into a global commercial business that will support its operations as it moves closer to launching its treatments for depression and migraine.

  March 28, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  COVID-19 Update: Contradictory J&J Data and a 4th Shot Likely for 50 Plus

  COVID-19 vaccines are the most-studied vaccines in history. This is partly why some data can appear so contradictory. For those and more COVID-19 stories, continue reading.

  March 28, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  AACR Preview: AstraZeneca to Showcase “Oncology Revolution”

  AstraZeneca will showcase its early oncology portfolio at the American Association for Cancer Research set to begin on April 8.

  March 28, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  BioForest

  Sana On Track to Remove Barriers for Cell & Gene Therapy

  Before cell and gene therapy can truly become mainstream medicine, the challenges of allogeneic rejection and targeted delivery must be solved. Sana Biotechnology is on the path to do that.

  March 28, 2022

   · 

  6 min read

   · 

  Gail Dutton
• 

  Business

  Bayer Stakeholder Temask May Call for CEO Baumann’s Ouster

  Per Bloomberg: Singapore-based Temask Holdings is calling for the installation of a new chief executive officer at Bayer.

  March 28, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Biogen and Ionis Suffer Another Defeat in ALS

  Biogen and Ionis Pharmaceuticals announced that their Phase I study of BIIB078 (IONIS-C9Rx) intended for ALS did not meet clinical endpoints, so they will discontinue the program.

  March 28, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  FDA

  FDA Limits Use of GSK & Vir’s COVID-19 Antibody Therapy

  The FDA amended its EUA for GlaxoSmithKline and Vir Biotechnology’s sotrovimab for COVID-19. The amendment relates specifically to the BA.2 Omicron sub-variant.

  March 28, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Global Roundup: RDIF Touts Efficacy of Sputnik V in HIV Patients

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  March 28, 2022

   · 

  4 min read

   · 

  Alex Keown